VOAM
NRXP icon

Vertex One Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Vertex One Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1.06M Hold
10,000
– – 0.24% 92
2019
Q3 		$1.06M Buy
+10,000
New +$1.05M 0.27% 95

Other funds holding NRXP

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vertex One Asset Management's NRXP Position: Q4 2019 in Review

Vertex One Asset Management held its NRX Pharmaceuticals (NRXP) position steady in Q4 2019 at 10,000 shares worth $1.06M. The position accounts for 0.24% of the portfolio, ranked #92.

Vertex One Asset Management first reported a position in NRXP in Q3 2019 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold NRXP as of Q4 2019.

  • Vertex One Asset Management held 10,000 shares of NRX Pharmaceuticals worth $1.06M as of Q4 2019.
  • Vertex One Asset Management left its NRX Pharmaceuticals share count unchanged in Q4 2019.
  • NRX Pharmaceuticals made up 0.24% of Vertex One Asset Management's portfolio in Q4 2019, its #92 holding.
  • Vertex One Asset Management first reported a position in NRX Pharmaceuticals in Q3 2019 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2019.

Based on Vertex One Asset Management's 13F filing for Q4 2019, filed 21 Jan 2020.